Please login to the form below

Not currently logged in
Email:
Password:

Sun gets FDA marketing nod for Protonix

Sun Pharmaceutical wins FDA approval for its ANDA to market a generic version of Wyeth's Protonix tablets

India-headquartered generic manufacturer Sun Pharmaceutical has won FDA approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Wyeth's Protonix tablets (pantoprazole).

Pantoprazole is indicated for the short-term treatment of erosive esophagitis associated with GERD, maintenance of healing of erosive esophagitis and for the treatment of hypersecretory diseases.

Sun's generic pantoprazole tablets are copies of Wyeth's Protonix Delayed Release Tablets and include 20 mg and 40 mg doses, both of which post annual US sales of around USD 2.3bn.

Sun, which was the first-to-file its generic Protonix ANDA with a Paragraph IV certification, also gains a 180-day marketing exclusivity.

Sun stated that it was now mulling its launch options.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...

Infographics